uric acid has been researched along with Prodromal Characteristics in 5 studies
Uric Acid: An oxidation product, via XANTHINE OXIDASE, of oxypurines such as XANTHINE and HYPOXANTHINE. It is the final oxidation product of purine catabolism in humans and primates, whereas in most other mammals URATE OXIDASE further oxidizes it to ALLANTOIN.
uric acid : An oxopurine that is the final oxidation product of purine metabolism.
6-hydroxy-1H-purine-2,8(7H,9H)-dione : A tautomer of uric acid having oxo groups at C-2 and C-8 and a hydroxy group at C-6.
7,9-dihydro-1H-purine-2,6,8(3H)-trione : An oxopurine in which the purine ring is substituted by oxo groups at positions 2, 6, and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Serum uric acid (SUA) had been associated with incident hypertension, but it is uncertain whether and to what extent the effect of SUA is mediated by other metabolic factors." | 7.91 | Mediation of the effect of serum uric acid on the risk of developing hypertension: a population-based cohort study. ( Cao, Z; Cheng, Y; Gao, Y; Li, S; Li, W; Sun, L; Wang, Y; Yang, H; Yu, P, 2019) |
| "Our present study assessed the role of serum uric acid as a putative biomarker in a prodromal PD cohort [REM Sleep Behavior disorder (RBD) and Hyposmia] followed longitudinally." | 4.31 | Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study. ( Angelopoulou, E; Antonelou, R; Beratis, I; Bonakis, A; Bougea, A; Bregianni, M; Koros, C; Lourentzos, K; Pachi, I; Papadimitriou, D; Papageorgiou, SG; Papagiannakis, N; Prentakis, A; Simitsi, AM; Stamelou, M; Stanitsa, E; Stefanis, L; Trapali, XG, 2023) |
| "Serum uric acid (SUA) had been associated with incident hypertension, but it is uncertain whether and to what extent the effect of SUA is mediated by other metabolic factors." | 3.91 | Mediation of the effect of serum uric acid on the risk of developing hypertension: a population-based cohort study. ( Cao, Z; Cheng, Y; Gao, Y; Li, S; Li, W; Sun, L; Wang, Y; Yang, H; Yu, P, 2019) |
| "The global burden of Parkinson's disease (PD) has increased from 2." | 2.82 | Parkinson's Disease: Risk Factor Modification and Prevention. ( Kaas, B; Rajan, S, 2022) |
| "Both BMI and urate are independent predictors of dementia, and there are inverse monotonic and dose-response associations of BMI and urate with dementia." | 1.56 | Associations of BMI and Serum Urate with Developing Dementia: A Prospective Cohort Study. ( Cao, Z; Li, S; Wang, Y; Xu, C; Xu, F; Yang, H; Zhang, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 3 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rajan, S | 3 |
| Kaas, B | 3 |
| Koros, C | 1 |
| Simitsi, AM | 1 |
| Papagiannakis, N | 1 |
| Bougea, A | 1 |
| Prentakis, A | 1 |
| Papadimitriou, D | 1 |
| Pachi, I | 1 |
| Beratis, I | 1 |
| Stanitsa, E | 1 |
| Angelopoulou, E | 1 |
| Antonelou, R | 1 |
| Bregianni, M | 1 |
| Lourentzos, K | 1 |
| Papageorgiou, SG | 1 |
| Bonakis, A | 1 |
| Trapali, XG | 1 |
| Stamelou, M | 1 |
| Stefanis, L | 1 |
| Cao, Z | 2 |
| Xu, C | 1 |
| Yang, H | 2 |
| Li, S | 2 |
| Xu, F | 1 |
| Zhang, Y | 1 |
| Wang, Y | 2 |
| Cheng, Y | 1 |
| Sun, L | 1 |
| Gao, Y | 1 |
| Yu, P | 1 |
| Li, W | 1 |
| Dmitriev, VA | 1 |
| Oshchepkova, EV | 1 |
| Titov, BN | 1 |
| Rogoza, AN | 1 |
| Saidova, MA | 1 |
| Bolotova, MN | 1 |
| Gushchina, OV | 1 |
| Polevaia, TY | 1 |
1 review available for uric acid and Prodromal Characteristics
| Article | Year |
|---|---|
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
Parkinson's Disease: Risk Factor Modification and Prevention.
Topics: Humans; Parkinson Disease; Prodromal Symptoms; Risk Factors; Uric Acid | 2022 |
1 trial available for uric acid and Prodromal Characteristics
| Article | Year |
|---|---|
[Is there an association of uric acid level with preclinical target organ damage in moderate- and high-risk hypertensive patients?].
Topics: Adult; C-Reactive Protein; Female; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; | 2013 |
3 other studies available for uric acid and Prodromal Characteristics
| Article | Year |
|---|---|
Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study.
Topics: Anosmia; Biomarkers; Humans; Parkinson Disease; Prodromal Symptoms; REM Sleep Behavior Disorder; Uri | 2023 |
Associations of BMI and Serum Urate with Developing Dementia: A Prospective Cohort Study.
Topics: Adult; Aged; Body Mass Index; Cohort Studies; Dementia; Disease Progression; Female; Follow-Up Studi | 2020 |
Mediation of the effect of serum uric acid on the risk of developing hypertension: a population-based cohort study.
Topics: Adult; Aged; Aged, 80 and over; China; Cohort Studies; Cross-Sectional Studies; Female; Follow-Up St | 2019 |